ABSTRACT
Bacterial co-infections are typically associated with viral respiratory tract infections and pose a significant public health problem around the world. COVID-19 infection damages tissues lining the respiratory track and regulates immune cells/cytokines leading to microbiome dysbiosis and facilitating the area to be colonized by pathogenic bacterial agents. There have been reports of different types of bacterial co-infection in COVID-19 patients. Some of these reports showed despite geographical differences and differences in hospital settings, bacterial co-infections are a major cause of morbidity and mortality in COVID-19 patients. The inappropriate use of antibiotics for bacterial infections, particularly broad-spectrum antibiotics, can also further complicate the infection process, often leading to multi drug resistance, clinical deterioration, poor prognosis, and eventually death. To this end, researchers must establish a new therapeutic approach to control SARS-CoV-2 and the associated microbial coinfections. Hence, the aim of this review is to highlight the bacterial co-infection that has been recorded in COVID-19 patients and the status of antimicrobial resistance associated with the dual infections.
Acknowledgement
The work was supported by the Scientific Grant Agency of the Ministry of Education, Science, Research, and Sport of the Slovak Republic and the Slovak Academy Sciences [IFPDP-100-22].
Disclosure statement
No potential conflict of interest was reported by the author(s).
Consent for publication
All authors have provided consent for the manuscript to be published.
Credit authorship contribution statement
Addisu D. Teklemariam, Anwar M. Hashem, Saber H. Saber, Mohammed S. Almuhayawi, Shafiul Haque, Turki S. Abujamel, Steve Harakeh: Writing and revision the manuscript.
Data availability statement
All data generated or analyzed during this study are included in this published article.